
Data as of Nov 22, 2026, 5:15 PM UTC · policy pm-quality-4
Chart and changes show stored historical probabilities, not the selected live book.
Trends
Selected row: book midpoint. Other rows: stored references, possibly normalized; 24h changes use stored history.
Venue terms
Source: Polymarket
Informational venue terms only; CoinRithm paper trading uses its own rules.
Market depth · No
Loading selected book…
—
Related Markets
Related questions for context, not a comparison of equivalent contracts.
FDA approves skin cancer vaccine by which date?
FDA approves YCT-529 male birth control pill before 2035?
FDA Approves Openwater Cancer Treatment by 2032
Will Texas expand Medicaid?
How many US births in 2026?
Hantavirus pandemic in 2026?
Rules
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
Free JSON for this market, no API key needed:
https://api.coinrithm.com/api/prediction-markets/events/polymarket/fda-approves-retatrutide-this-yearAI agents: call pm_data_event on the CoinRithm MCP server:
https://mcp.coinrithm.com/mcp+4 more outcomes
+3 more outcomes
+5 more outcomes